Cero Therapeutics Holdings annual stock-based compensation
2021
2022
2023
2024
2025
Cero Therapeutics Holdings Stock-Based Compensation Growth & History (CERO)
Cero Therapeutics Holdings's stock-based compensation was $1.1M for fiscal 2025.
View full Cero Therapeutics Holdings company overviewCero Therapeutics Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | $171,388 | +18.54% |
| 2024 | 2024-12-31 | $924,668 | $827,772 | +854.29% |
| 2023 | 2023-12-31 | $96,896 | −$284,174 | −74.57% |
| 2022 | 2022-12-31 | $381,070 | $93,335 | +32.44% |
| 2021 | 2021-12-31 | $287,735 | — | — |
Cero Therapeutics Holdings quarterly stock-based compensation
Q1.23
Q2.23
Q3.23
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.1M | $938,757 | +512.06% |
| Q1 2026 | 2026-03-31 | $1.6M | $1.3M | +430.41% |
| Q4 2025 | 2025-12-31 | $259,666 | — | — |
| Q3 2025 | 2025-09-30 | $348,116 | $328,116 | +1640.58% |
| Q2 2025 | 2025-06-30 | $183,328 | $153,328 | +511.09% |
| Q1 2025 | 2025-03-31 | $304,946 | — | — |
| Q3 2024 | 2024-09-30 | $20,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $30,000 | −$1.4M | −97.86% |
| Q3 2023 | 2023-09-30 | $20,000 | — | — |
| Q2 2023 | 2023-06-30 | $1.4M | — | — |
| Q1 2023 | 2023-03-31 | $28,144 | — | — |
Cero Therapeutics Holdings stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Cero Therapeutics Holdings's stock-based compensation increased from $287,735 to $1.1M, a change of $808,321. The latest reported quarter, Q2 2026, shows $1.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cero Therapeutics Holdings source filings ↗